Breast Conserving Surgery (BCS) is Superior to Mastectomy in Early Stage Triple Negative Breast Cancer (TNBC) a Comparative Study

Abstract

Background: Breast cancer is the most prevalent form of cancer in women worldwide and the second-leading cause of death from cancer in women. Because the estrogen receptor, progesterone receptor, and HER2 are not expressed, triple-negative breast cancer (TNBC) has an aggressive clinical history. The highest rates of recurrence and survival, higher average grades, and larger tumor sizes at diagnosis are all characteristics of TNBC. Objective: To compare between breast conserving surgery (BCS) and mastectomy patients with early stage Triple negative breast cancer (TNBC). Materials and Methods: We conducted a comparative retrospective monocentric study that evaluated TNBC patients treated with upfront surgery at CMH Dhaka, CMH Bogura and Kurmitola General Hospital, Dhaka. The observation period was from 1 January 2021 to 31 December 2022. All patients received biopsy to obtain the pathological tissue before treatment, and their immunohistochemical results met the diagnostic criteria for TNBC. Study patients divide din to two group 40 surgeries with primary site were categorized as receiving BCS and other hand 40 surgeries with categorized as receiving mastectomy. BCSS and OS were the primary outcomes of our study. Results: Tumor grade II, tumor size >20.0 mm and lymph node 2 were significantly associated with breast cancer-specific survival. Tumor size >20.0 mm and lymph node 2 were significantly associated with TNBC survival. Conclusion: TNBC is a breast cancer type that is aggressive and has a bad prognosis. With regard to breast cancer-specific survival, advanced age, being single, left side of laterality, tumor grades II and III, large tumor size, and lymph node 2 were all substantially related.